May 2024 FDA Recall Duloxetine by Breckenridge Pharmaceutical, Inc
D-0562-2024 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Breckenridge Pharmaceutical, Inc on May 17, 2024 for the product Duloxetine. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0562-2024

Reason for Recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Initiated
05-17-2024
Reported
06-26-2024
Quantity
165,678, 90-count bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Breckenridge Pharmaceutical, Inc
Nationwide in the USA
Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Batch or Lot Expiration Information

Lot# : 230035C, Exp. date 11/30/2025; 230101C, Exp. date 12/31/2025